Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 9/11/2018
SIETES contiene 92577 citas

 
 
 1 a 20 de 165 siguiente >>
Presentar resultados
Seleccionar todas
3.Enlace a cita original Cita con resumen
Park Y, Bateman BT, Kim DH, Hernandez-Diaz S, Patorno E, Glynn RJ, Mogun H, Hyubrechts KF. Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study. BMJ 2018;360:28 de marzo. [Ref.ID 102642]
4.Enlace a cita original Cita con resumen
Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 2018;360:8 de marzo. [Ref.ID 102640]
5.Enlace a cita originalTiene citas relacionadas Cita con resumen
Gill SS, Bai AD. Beta testing the potential link between the alpha antagonist tamsulosin and dementia. Pharmacoepidemiol Drug Saf 2018;27:marzo. [Ref.ID 102635]
6.Enlace a cita original Cita con resumen
Uyhazi KE, Miano T, Pan W, VanderBeek BL. Association of novel oral antithrombotics with the risk of intraocular bleeding. Jama Ophthalmol 2017:14 de diciembre. [Ref.ID 102190]
8. Cita con resumen
Khan AR, Bavishi C, Riaz H, Farid TA, Khan S, Atlas M, Hirsch G, Ikram S, Bolli R. Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. Circulation: Cardiovascular Quality and Outcomes 2017;10:e003153. [Ref.ID 101377]
9.Tiene citas relacionadas Cita con resumen
Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G, on behalf of the Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016;354:i4857. [Ref.ID 100756]
10.Tiene citas relacionadas Cita con resumen
Gislason GH, Torp-Pedersen C. NSAIDs and the failing heart. BMJ 2016;354:i5163. [Ref.ID 100755]
11.Tiene citas relacionadas Cita con resumen
Larsen TB, Nielsen PB. Stroke and mortality after atrial fibrillation—a global struggle. Lancet 2016;388:1131-2. [Ref.ID 100749]
12.Tiene citas relacionadas Cita con resumen
Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, Commerford P, Jansky P, Avezum A, Sigamani A, Demasceno A, Reilly P, Grinvalds A, Nakamya J, Aje A, Almahmeed W, Moriarty A, Wallentin L, Yusuf S, Connolly SJ, on behalf of the RE-LY Atrial Fibrillation Registry and Cohort Study Investigators. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet 2016;388:1161-9. [Ref.ID 100676]
13.Tiene citas relacionadas Cita con resumen
Odutayo A, Wong CX, Hsiao A, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ 2016;354:i4482. [Ref.ID 100671]
14.Tiene citas relacionadas
Wang C, Wong S, Graham DJ. Risk of anaphylaxis with intravenous iron products. JAMA 2016;315:2232-3. [Ref.ID 100367]
15.Tiene citas relacionadas
DeLoughery TG. Risk of anaphylaxis with intravenous iron products. JAMA 2016;315:2232. [Ref.ID 100366]
16.Tiene citas relacionadas Cita con resumen
Wong AYS, Root A, Dogulas IJ, Chui CSL, Chan EW, Ghebremichael-Weldeselassie Y, Siu CW, Smeeth L, Wong ICK. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 2016;352:h6926. [Ref.ID 99982]
17.Tiene citas relacionadas Cita con resumen
Iyer G, Alexander GC. Cardiovascular risks associated with clarithromycin. BMJ 2016;352:i23. [Ref.ID 99980]
18.Tiene citas relacionadas Cita con resumen
Holman RR, Peterson ED. Sitagliptin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:2479. [Ref.ID 99762]
19.Tiene citas relacionadas Cita con resumen
Rutter MK, Wright AK, Ashcroft DM. Sitagliptin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:2478. [Ref.ID 99761]
20. Cita con resumen
Andersen NN, Pasternak B, Andersson M, Nielsen NM, Jess T. Risk of demyelinating diseases in the central nervous system in patients with inflammatory bowel disease treated with tumor necrosis factor inhibitors. JAMA Intern Med 2015;175:1990-2. [Ref.ID 99751]
Seleccionar todas
 
 1 a 20 de 165 siguiente >>